Part, Chapter, Paragraph

 1 I, 1,1(2)   |         McCracken B.H., Schlegel J.U., et al. Renal heterotransplantation
 2 I, 1,1(3)   | Nehlsen-Canarella S.L., Concepcion W., et al. Baboon-to-human cardiac
 3 I, 1,1(4)   |                Fung J.J., Tzakis A.G., et al., Baboon-to-human liver
 4 I, 1,1(9)   |                C., Ye Y., Rolf J.L.L., et al., The Pig as Potential
 5 I, 1,1(10)  |             Vangerow B., Schmidtko J., et al., Acute vascular rejection
 6 I, 1,1(10)  |               Bhatti F., Schmoeckel M. et al., Long-term survival
 7 I, 1,1(10)  |               Ostlie D.J., Bhatti F.N. et al., Life-supporting function
 8 I, 1,1(10)  |               Schmoeckel M., Zaidi A., et al., Three-month survival
 9 I, 1,1(10)  |               Quinn C.M., Martin M.J., et al., A human CD46 transgenic
10 I, 1,1(10)  |              Weidner B.C., Byrne G.W., et al., The role of antibodies
11 I, 1,1(11)  |             T.E., Rao A.S., Murase N., et al., Will xenotransplantation
12 I, 2,2(13)  |              Fischel R.J., Matas A.J., et al., Immunopathology of
13 I, 2,2(13)  |        Vercellotti G.M., Fischel R.J., et al., Mechanisms of complement
14 I, 2,2(14)  |             Cooper D.K.C., Malcom A.J. et al., Identification of carbohydrate
15 I, 2,2(14)  |          Vaughan H.A., Dabkowski P.L., et al., Anti-pig IgM antibodies
16 I, 2,2(15)  |               R., John R., Fryer J.P., et al., Removal of baboon and
17 I, 2,2(15)  |               C., Lexer G., Rose A.G., et al., Effects of cyclosporine
18 I, 2,2(15)  |                  Soares M., Havaux X., et al., Depletion of IgM xenoreactive
19 I, 2,2(15)  |                Hallberg E., Bjorck S., et al., Studies on the removal
20 I, 2,2(16)  |                Clark D.S., Finstad J., et al., Role of the complement
21 I, 2,2(16)  |             Kirk D.A., Bollinger R.R., et al., The effect of soluble
22 I, 2,2(16)  |              Neethling F.A., Koren E., et al., In vitro and in vivo
23 I, 2,2(16)  |           Rollins S.A., Dalmasso A.P., et al., Complement inhibition
24 I, 2,2(17)  |                M.A., Vercellotti G.M., et al., Accomodation: a working
25 I, 2,2(18)  |               Quinn C.M., Martin M.J., et al., A human CD46 transgenic
26 I, 2,2(18)  |             Williams B.L., Matis L.A., et al., Expression of a functional
27 I, 2,2(18)  |           Kooyman D.L., Alvarado C.G., et al., Human complement regulatory
28 I, 2,2(18)  |                  Aminian A., Barlow H. et al., Renal xenografts from
29 I, 2,2(18)  |                M., Forni M., Varzi V., et al., Sperm-mediated gene
30 I, 2,2(19)  |             Fodor W.L., Mouhtouris E., et al., Enzymatic remodeling
31 I, 2,2(20)  |          Soares M.P., Lin Y., Sato K., et al., Pathogenesis of and
32 I, 2,2(22)  |               Bhatti F., Schmoeckel M. et al., Long-term survival
33 I, 2,2(22)  |               Ostlie D.J., Bhatti F.N. et al., Life supporting function
34 I, 2,2(26)  |                  Ferran C., Soares M., et al., Modification of vascular
35 I, 2,3(27)  |          Soares M.P., Lin Y., Sato K., et al., Pathogenesis of and
36 I, 2,3(27)  |              den Bogarde J., Forty J., et al., Prolonged Survival
37 I, 2,3(28)  |              den Bogarde J., Forty J., et al., Prolonged Survival
38 I, 2,3(29)  |          Soares M.P., Lin Y., Sato K., et al., Accommodation, Immunol
39 I, 2,3(30)  |          Soares M.P., Lin Y., Sato K., et al., Accommodation, Immunol
40 I, 2,3(30)  |                  Soares M.P., Sato K., et al., Accommodated xenografts
41 I, 2,3(31)  |               Latinne D., Gianello P., et al., Preformed cytotoxic
42 I, 2,3(32)  |               Bhatti F., Schmoeckel M. et al., Long-term survival
43 I, 2,3(32)  |               Ostlie D.J., Bhatti F.N. et al., Life supporting function
44 I, 2,3(33)  |           Kooyman D.L., Alvarado C.G., et al., Human complement regulatory
45 I, 2,3(33)  |           Yannoutsos N., Langford G.A. et al., Effect of transgenic
46 I, 2,3(34)  |               Bhatti F., Schmoeckel M. et al., Long-term survival
47 I, 2,3(34)  |                Schmoeckel M., Zaidi A. et al., Three-month survival
48 I, 2,3(34)  |           Kooyman D.L., Alvarado C.G., et al., Human complement regulatory
49 I, 2,3(35)  |                Schmoeckel M., Zaidi A. et al., Three-month survival
50 I, 2,3(36)  |               Ostlie D.J., Bhatti F.N. et al., Life supporting function
51 I, 2,3(37)  |               Bhatti F., Schmoeckel M. et al., Long-term survival
52 I, 2,4(38)  |           Cooper D.K., Alexander T.J., et al., An approach to the
53 I, 2,4(42)  |                THE XEN111 Study group, et al., 1999, Search for cross-species
54 I, 2,5(43)  |                Chen S.H., Vaught T.D., et al., Cloned pigs produced
55 I, 2,5(43)  |                  Iwamoto M., Akita T., et al., Pig cloning by microinjection
56 I, 3,6(45)  |               Korsgren 0., Tibell, A., et al., Transplantation of
57 I, 3,6(47)  |                 Mancini A., Amoroso P. et al., Functional evaluation
58 I, 3,6(48)  |                  Keogh A.M., Brink J., et al., Report of the xenotransplantation
59 I, 3,6(49)  |               Bhatti F., Schmoeckel M. et al., Long-term survival
60 I, 3,6(49)  |               Ostlie D.J., Bhatti F.N. et al., Life supporting function
61 I, 3,6(49)  |                Schmoeckel M., Zaidi A. et al., Three-month survival
62 II, 2,12(64)|              Fishman J.A., Daniels N., et al., Uncertainty in Xenotransplantation: 
63 II, 2,12(64)|            pour les Sciences de la vie et de la santé (France), Avis
64 II, 2,12(64)|            France), Avis sur l'éthique et la xénotransplantation,
65 II, 2,14(68)|                  Blumer E.C., Quine S. et al., Aversion to Xenotransplantation,
66 II, 2,14(68)|             1995, p. 677; Mohacsi P.J. et al., Patients attitudes